NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Senti, If the PsPD problem had not been solved well before February 2017, NWBO would most likely not have been able to report that about 25% of the patients were still PFS at that time, 30 months after midpoint enrollment (if you assume that 248 events were reached during November 2016). One can speculate that had they not at least drastically reduced the reporting of false progressors as true progressors, NWBO would have (falsely) reported much earlier that 248 (75%) had progressed. The fact that the 75% progression was announced at the same time as the lifting of the screening halt was probably related to the PSpD problem and not at all coincidental. Also looking at the various trials I have not seen any that were employing patients with a normal (unedited) distribution of ages, sex, and GBM markers where the PFS approached 25% after 30 months on trial.